Related Experiment Video
Updated: May 22, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Current Status and Future Perspectives of CXCR4-based Radio-theranostics in Human Cancers: A Review
Baljinder Singh1, Ankit Watts2, Harneet Kaur3
1Professor and Head, Department of Nuclear Medicine.
CXCR4 receptors are overexpressed in many cancers, driving tumor growth and metastasis. Ga-68 Pentixafor PET/CT offers effective whole-body imaging for CXCR4-positive cancers, aiding diagnosis and prognosis.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Chemokine receptor CXCR4 is overexpressed in over 30 human cancers.
- CXCR4 overexpression correlates with tumor aggressiveness, metastasis, and recurrence, indicating poor prognosis.
- CXCR4 presents a viable target for cancer imaging and therapy.
Purpose of the Study:
- To review the diagnostic and prognostic utility of Ga-68 Pentixafor PET/CT.
- To discuss the theranostic potential of Ga-68 Pentixafor and Lu-177/Y-90 Pentixather as a pair.
- To explore applications in hematological and solid cancers.
Main Methods:
- Review of literature on Ga-68 Pentixafor PET/CT and Lu-177/Y-90 Pentixather.
- Analysis of CXCR4 receptor expression in various cancers.
- Evaluation of imaging characteristics and theranostic applications.
Main Results:
- Ga-68 Pentixafor PET/CT demonstrates high affinity for CXCR4, enabling efficient whole-body imaging.
- This PET probe provides significant diagnostic and prognostic information in human cancers.
- Favorable radiolabeling efficiency, stability, and safety profile of Ga-68 Pentixafor are reported.
Conclusions:
- Ga-68 Pentixafor PET/CT is a valuable tool for CXCR4-targeted cancer imaging.
- The theranostic pair Ga-68 Pentixafor and Lu-177/Y-90 Pentixather shows promise for hematological and solid tumors.
- Targeting CXCR4 offers a promising strategy for cancer theranostics.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
08:32Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers